logo
  Join        Login             Stock Quote

An Insider Buys $300K Of CVS Caremark Corporation (CVS), Should Investors Follow?

 October 08, 2012 06:41 PM
 


(By Rich Bieglmeier) Insiders were on vacation or tight with their dinero last week. Insider activity was super-slow last week. iStock only found two buys of interest, LiveDeal, Inc. (LIVE) and CVSCaremark Corporation (CVS). LIVE looks like a short to us; so, CVS is the only game in town, in our view.

Last week, EVP & General Counsel, Thomas Moriarty bought 6,164 shares at $48.67, for an investment of $300,002. The purchase is more interesting in light of how close the price paid is to CVS's 52-week, intraday high of $49.23.

Moriarty was named Executive Vice President and General Counsel of CVS Caremark on Sept. 17, 2012. Despite his short stint with the company, he felt confident enough to chalk up $300 large, at a 52-week high. Did we mention that already?

[Related -Express Scripts Holding Company (ESRX): Should You Own ESRX in 2014?]

According to iStock's take on the chart, Mr. Moriarty might have been better off waiting a couple of days or weeks. The stock looks heavy at the top and appears to be rounding back to minor support at $38. There is a more robust firewall between $46 and $43.

Relative to its industry, CVS Caremark is fairly priced. The average P/E for the peer group is 17.46, while the drug store chain trades at 17.39 time earnings. CVS's is valued at 53 cents for every dollar in revenue per share, and the industry for 45 cents. However, its growth

For 2013, Wall Street is projecting $3.79, up 12.50% from 2012. Meanwhile, CVS has a forward P/E of 12.85. By this metric, CVS offers very little room for price-to-earnings expansion.  If anything, iStock would be surprised to see the company's multiple contract as sales growth is expected to slow to 4.2% in the year ahead, down from 14.70% in 2012.

[Related -AFLAC Incorporated (AFL), CVS Caremark Corporation (CVS)A-List Dividend Duo]

Slowing sales could open the door to downside earnings surprises, something that has only occurred once in the last 16 quarterly checkups. However, the recipe is in place for at least one disappointing quarter in the next year as CVS' cost of revenues (COR) has increased as a percentage of revenue, and as compared to the first three and six months of 2011.

For the first half of 2011, CORs consumed 81.1% of revenue. In the quarter ended June 30, 2011, the number was 80.7%. For 2012, the percentages are 83% and 82.2%, respectively. Rising costs and slowing sales could put the clamp on earnings, especially if the economy continues to cool.

Overall, iStock feels the potential risk to earnings, and current valuations make CVS Caremark Corporation (CVS) too pricey in our view. We'd find the stock more attractive at $39ish than Thomas Moriarty's buy at $48.67.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageSector Detector: Bulls Go Down Swinging, Refusing To Give Up Much Ground

Although the stock market displayed weakness last week as I suggested it would, bulls aren’t going down read on...

article imageThe Bumpy Road Ahead To Policy Normalization

When the dust clears from tomorrow’s Fed announcement, the crowd’s expecting that the slow but persistent read on...

article imageAnalyzing Performance Histories That Might Have Been

The trend in recent years of securitizing more of the world’s market betas offers investors, in theory, read on...

article imageBig Prints in VIX Calls

The CBOE Vix Index is in positive territory on Friday morning as shares in the S&P 500 Index move slightly read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.